Deadline for early bird registration
15 June 2017



Scientific Programme
Click here for program at a glance.

Time Wednesday 6th
9:15-17:00 Alsh Dialysis masterclass
10:00-17:00 Boisdale Enuresis masterclass
11:30-17:00 Dochart 1 The ESPN and evolution of renal care for children in Europe
17:30 Opening Ceremony (Lomond auditorium)
19:00-21:00 Welcome Reception in Glasgow Science Centre
Time Thursday 7th
Alsh Personal practice: Optimising growth in CKD
Dieter Haffner
Boisdale Personal practice: How I treat and investigate neonatal hypertension
David Hughes
08:45-10:15 Parallel sessions
Lomond auditorium
ESPN WG session: The past, present and future of paediatric CAKUT, UTI and bladder disorders.
08:45 Advances and new horizons in genetics of CAKUT
Stephanie Weber
09:15 Bladder dysfunction in the paediatric recipient
Ann Raes
09:45 Oral presentations
O-001 Oral antibiotic treatment for pyelonephritis is safe and effective if there is a formalised contact to the Department of Paediatrics
Line Thousig Sehested - Copenhagen University Hospital Hvidovre, Denmark
O-002 Role of fetal MRI in antenatally detected renal anomalies
Tina Thekkekkara - Sheffield Children’s NHS Foundation Trust, United Kingdom
O-003 Value of renal and bladder ultrasound in diagnosing vesicoureteral reflux
Amina El Amouri - Universitair Ziekenhuis Brussel, Belgium
O-004 First-year profile of biomarkers for early detection of renal injury in healthy infants
Dusan Kostic - Childrens Institute - University of Sao Paulo, Brazil
Have clinical trials changed paediatric nephrology practice? And late breaking clinical trials.
08:45 Clinical trials in paediatric nephrology and how they have changed practice
Arvind Bagga
09:15 Which trials are needed in paediatric nephrology and how can these be realised?
Nick Webb
09:45 Oral presentations
O-005 Long-term lifestyle intervention improves renal function in obese children and adolescents
Mark van Dam - Maastricht University Medical Centre, The Netherlands
O-006 Utility of performing voiding cystourethrogram (VCUG) with antibiotic - an open labelled randomized control trial.
Rajiv Sinha - Institute of Child Health, Kolkata, India
O-007 Lower prednisone dosing for nephrotic syndrome relapse: a prospective randomized study
Amit Dagan - Institute of Nephrology, Schneider Children’s Medical Center, Israel
O-008 Standard vs. extended course prednisolone therapy for the presenting episode of steroid sensitive nephrotic syndrome: the PREDNOS study
Nick Webb - Royal Manchester Children’s Hospital, United Kingdom
New ways of dialysing children
08:45 Nocturnal and home haemodialysis
Dominik Muller
09:15 Advances in neonatal and infant dialysis
Heather Lambert
09:45 Oral presentations
O-009 Modification of young adult outcomes on haemodialysis - changing “our” practice
Marie-Louise Turner - St George’s University Hospitals NHS Foundation Trust, London, United Kingdom
O-010 Early changes in PD membrane morphology with low GDP fluids
Betti Schaefer - Center for Pediatric and Adolescent Medicine, University of Heidelberg, Germany
O-011 Effects of haemodiafiltration (HDF) vs conventional haemodialysis (HD) on growth and cardiovascular markers in children - data from the HDF vs HD (3H) study
Rukshana Shroff - Great Ormond Street Hospital for Children, London, United Kingdom
O-012 Hemodiafiltration is associated with reduced inflammation and oxidative stress and improved endothelial risk profile compared to high-flux hemodialysis in children
Ayse Agbas - Department of Pediatric Nephrology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey
PLENARY SESSION (Lomond auditorium):
The glomerular basement membrane – friend or foe?
Jeff Miner
11:00-11:30 Coffee Break and Exhibition: Halls 1&2
11:30-13:00 Parallel sessions
Lomond auditorium
JOINT SESSION ESPU: Can we fix congenital renal tract abnormalities? Will we be able to do this better in the future?
11:30 Could we fix renal malformations by mixing genetics and developmental biology with regenerative medicine?
Adrian Woolf
12:00 When and how to surgically fix antenatally damaged kidneys?
Guy Bogaert
12:30 Oral presentations
O-013 Bladder function at 10 years of age in boys with posterior urethral valves (PUV)
Riccardo Manuele - Evelina Children’s Hospital, London, United Kingdom
O-014 Clinical characteristics of pediatric urinary tract infection with negative urine leukocyte esterase test
Shojiro Okamoto - Tokai University Hachioji Hospital, Japan
O-015 Adolescents with posterior urethral valves: kidney and bladder function at transition to adult care.
Michal Maternik - Department of Paediatrics, Nephrology and Hypertension, Medical University of Gdansk, Poland
O-016 GDNF controls ureter length by regulating collecting duct progenitor expansion
Satu Kuure - University of Helsinki, Finland
Translating basic scientific discoveries into improved patient care
11:30 Identifying new therapeutic targets in the nephron through a genetic approach
Detlef Bockenhauer
12:00 Novel genetic insights into vitamin D and calcium metabolism
Karl Peter Schlingmann
12:30 Oral presentations
O-017 Mutations in the leukemia inhibitory factor receptor (LIFR) gene and Lifr deficiency cause urinary tract malformations
Dieter Haffner - Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Germany
O-018 Australian renal gene panels: results from a national diagnostic service
Hugh McCarthy - Children’s Hospital at Westmead, Sydney, Australia
O-019 Exome sequencing for the identification of candidate genetic variants in renal hypodysplasia paediatric patients
Susanna Negrisolo - Laboratory of Immunopathology and Molecular Biology of The Kidney, Women’s And Children’s Health Department, University of Padua, Italy
O-020 Soluble urokinase plasminogen activator receptor (suPAR) serum levels predict progression of kidney disease in children
Franz Schaefer - Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Germany
Advances in the diagnosis and treatment of Alport syndrome and thin membrane disease
11:30 Mechanisms underpinning Alport syndrome which will improve patient care
Rachel Lennon
12:00 Therapeutic options in Alport syndrome
Oliver Gross
12:30 Oral presentations
O-021 Collagen (COL4) mutations in steroid-resistant nephrotic syndrome (SRNS) in children
Larisa Prikhodina - Research Institute of Pediatrics, Pirogov Russian National Research Medical University
O-022 Targeting the type IV collagen misfolding in hereditary nephritis Alport syndrome
Kohei Omachi - Kumamoto University, Japan
O-023 Clinical genetic testing using next generation sequencing in steroid-resistant nephrotic syndrome and Alport syndrome
Ethan Sen - School of Clinical Sciences, University of Bristol, United Kingdom
O-024 STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model
Tsubasa Yokota - Kumamoto University, Japan
13:00 Lunch / Posters: Halls 1&2
13:00-14:00 Industry symposium 1 (Lomond auditorium)
14:00-14:30 Moderated poster session: Hall 2
14:30-16:00 Parallel sessions
Lomond auditorium JOINT SESSION ERA-EDTA:  Can we prevent cardiovascular disease developing in children and adults with kidney disease?

Hypertension control and RAAS blockade: Lessons from adult studies and room for improvement in children?
Mustafa Arıcı
Uromodulin, kidney function and cardiovascular disease
Olivier Devuyst
What needs to be targetted in CKD children to reduce their lifetime risk of cardiovascular disease?
Lesley Rees
New ways of modifying the immune system to treat kidney disease
14:30 Immune profiling of cells
Eoin McKinney
15:00 Translating results of comprehensive complement studies into clinical practice
Christoph Licht
15:30 Oral presentations
O-025 Double filtration plasmapheresis - 10-year experience as an alternative to plasma exchange
Andrew Maxted - Nottingham Children’s Hospital, United Kingdom
O-026 IL-10 Polymorphisms in children with tubulointerstital nephritis and uveitis
Sari Rytkönen - Pedego Research Unit and Medical Research Center (MRC), Oulu University Hospital, Finland
O-027 IL-10 as a potential mediator in parenchymal damage in children with congenital anomalies of the kidney and urinary tract
Emiliya Kostadinova - Trakia University, Medical Faculty, Bulgaria
O-028 Tocilizumab (anti-IL6 receptor) as a potential treatment for idiopathic nephrotic syndrome
Marie Magnavacca - Hôpital Robert-Debré, Paris, France
Kidney Research UK sponsored session: Using information technology to improve patient care
14:30 AI-enabled healthcare
Dom King
15:00 The power of social media
Tom Oates
15:30 Oral presentations
O-029 Successfully implementing transition by addressing common misconceptions and use of the Ready Steady Go transition programme
Arvind Nagra - Southampton Children’s Hospital, United Kingdom
O-030 Acute pediatric nephrology simulation
Mostafa Elbaba, Hamad Medical Corporation, Qatar
O-031 All-cause mortality and cardiovascular disease incidence in patients with childhood-onset end-stage renal disease in Scotland
Dinara Galiyeva - Usher Institute of Population Health Sciences and Informatics, Universıty of Edinburgh, Scotland
O-032 Causes of non-elective hospitalizations in children with chronic kidney disease (CKD): findings from the 4c study
Jitka Lachova - University Hospital Motol, Prague, Czech Republic
16:00-16:15 Exhibition: Halls 1&2
PLENARY SESSION (Lomond auditorium):
Global advancements in preventing and treating kidney disease.
Still a long way to go

John Feehally
17:00-18:00 Parallel sessions
Lomond auditorium Young nephrologists’ session

Becoming a new paediatric nephrologist and balancing clinical work, clinical and lab research and family..!
Djalila Mekahli - Ana Teixeira - Louise Oni - Caner Alparslan
17:00-18:30 Industry symposium 2 (Alsh)
17:00-18:30 Industry symposium 3 (Boisdale)
18:30 Fun Run
Time Friday 8th
7:45-8:45 Industry symposium 4 (Alsh)
7:45-8:45 Industry symposium 5 (Carron)
Lomond auditorium Personal practice: Therapy-resistant enuresis
Tryggve Neveus
Boisdale Personal practice: The child with a kidney stone
Ozan Ozkaya
8:45-9:30 PLENARY SESSION (Lomond auditorium):
Unlocking the genetic secrets of nephrotic syndrome
Friedhelm Hildebrandt
9:30-11:00 Parallel sessions
Lomond auditorium
ESPN WG session:  The past, present and future of paediatric CKD and bone disorders
09:30 Vitamin D treatment in children with CKD: guidelines of the ESPN CKD-MBD and dialysis
Justine Bacchetta
10:00 New insights of FGF23/Klotho system in CKD
Maren Leifheit-Nestler
10:30 Oral presentations
O-037 Evidence for "shrunken pore syndrome" in children
Emil den Bakker - Vu Medical Centre, The Netherlands
O-038 Elevated myocardial wall stress predicts left ventricular remodelling in children with chronic kidney disease
Haotian Gu - Kings College London, United Kingdom
O-039 The FGF23 and Klotho axis in pediatric chronic kidney disease - a prospective cohort study
Ylva Tranaeus Lindblad - Karolinska Institutet, Clintec, Division of Pediatrics, Sweden
O-040 Anthropometry and clinical outcomes in paediatric RRT - results from the ESPN/ERA-EDTA registry
Marjolein Bonthuis - ESPN/ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, The Netherlands
ESPN WG session: The past, present and future of paediatric transplantation
09:30 Update on cell therapies for the induction of tolerance after kidney transplantation
Christian Morath
10:00 Complement-binding DSA and antibody-mediated rejection
Jon Jin Kim
10:30 Oral presentations
O-033 Pre-emptive kidney transplantation is associated with improved graft survival in children: Data
from the French renal registry
Jérôme Harambat - Bordeaux University Hospital, France
O-034 Correlation of acoustic radiation force impulse (ARFI) elastography with histological findings in
pediatric renal transplant patients
Elke Wühl - Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Germany
O-035 Association of angiotensin II type 1 receptor antibodies with graft histology, function and
survival in paediatric renal transplant recipients
Alexander Fichtner - Department of Pediatrics I, University Children’s Hospital of Heidelberg, Germany
O-036 In vitro tacrolimus exposure in human proximal tubule cells results in differentially increased
CTGF expression in relation to the pharmacogenetic background for CYP3A5 and ABCB1.
Yasaman Ramazani - KU Leuven, Belgium
ESPN WG session: The past, present and future of idiopathic nephrotic syndrome
09:30 Treating idiopathic nephrotic syndrome...are steroids the answer?
Georges Deschenes
10:00 Changing environmental and epidemiological modulators of nephrotic syndrome
Claire Dossier
10:30 Oral presentations
O-041 Ubiquitin carboxyl-terminal hydrolase L1 is a podocyte target of IgG antibodies in idiopathic
nephrotic syndrome
Georges Deschenes - APHP Robert Debre, Paris, France
O-042 A single low dose schedule of rituximab is non-inferior to high dose and multiple dose schedules in the treatment of steroid sensitive frequently relapsing nephrotic syndrome
Andrew Maxted - Nottingham Children’s Hospital, United Kingdom
O-043 Is RAAS blockade effective in NPHS2 glomerulopathy?
Agnes Trautmann - Division of Pediatric Nephrology, University Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany
O-044 Risk factors for cardiovascular comorbidities in children with steroid-sensitive and steroid-resistant nephrotic syndrome
Fehime Kara Eroglu - Hacettepe University Faculty of Medicine, Division of Pediatric Nephrology, Ankara, Turkey
11:00-11:30 Coffee Break and Exhibition: Halls 1&2
11:30-13:00 Parallel sessions
Lomond auditorium
Advances in the diagnosis and treatment of TMA/HUS in children
11:30 Personalisation of eculizumab therapy in atypical HUS
Nicole van de Kar
12:00 Anti-complement factor H antibodies in kidney disease – pathogenesis and treatment
Arvind Bagga
12:30 Oral presentations
O-045 Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment
Elena Volokhina - Radboud University Medical Centre, Nijmegen, The Netherlands
O-046 Improved outcomes for paediatric patients with atypical haemolytic uraemic syndrome (aHUS) receiving long-term eculizumab treatment during on-treatment periods compared with off-treatment periods
Lars Pape - Hannover Medical School, Germany
O-047 Improved outcomes with prompt management of anti-factor H (FH) associated atypical hemolytic uremic syndrome (aHUS) in children: Trends from nationwide database
Priyanka Khandelwal - All India Institute of Medical Sciences, New Dehli, India
O-048 Genomic rearrangement events within complement factor H resulting in atypical haemolytic uraemic syndrome
Patrick Walsh - National Renal Complement Therapeutic Centre, Newcastle upon Tyne, United Kingdom
ESPN WG session: The past, present and future of inherited renal disorders
11:30 Diagnosis, treatment and mechanisms of nephrocalcinosis
Martin Konrad
12:00 Treatment, mechanism and prognosis of nephrogenic diabetes insipidus
Elena Levtchenko
12:30 Oral presentations
O-049 Targeted exome sequencing of a cohort of 204 patients identifies PBX1 as a novel gene involved in monogenic CAKUT
Laurence Heidet - APHP, Pediatric Nephrology Department, Reference Center MARHEA, Necker Hospital, Paris, France
O-050 Genomic imbalances in children with chronic kidney disease
Beata S. Lipska-Zietkiewicz - Department of Biology and Medical Genetics, Medical University of Gdańsk, Poland
O-051 Clinical manifestations of systemic oxalosis in primary hyperoxaluria type 1: when do which clinical manifestations occur?
Sander Garrelfs - Department of Pediatric Nephrology, Emma Children’s Hospital, University of Amsterdam, The Netherlands
O-052 Familial mediterranean fever in patients diagnosed with Fabry disease prevalence
Ipek Akil - Celal Bayar University, Manisa, Turkey
ESPN WG session: The past, present and future of paediatric dialysis
11:30 What is the best way to use peritoneal dialysis in our children?
Aleksandra Zurowska
12:00 Hemodiafiltration: is this a superior dialysis modality for children?
Rukshana Shroff
12:30 Oral presentations
O-053 Feasibility and tolerability of sustained low efficiency dialysis (SLED) in critically sick paediatric patients: a multicentric retrospective study
Rajiv Sinha - Institute of Child Health, Kolkata, India
O-054 Running a successful paediatric home haemodialysis service: overcoming treatment risks at home
Louise Pittendrigh - Royal Hospital for Children, Glasgow, United Kingdom
O-055 A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric subjects with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
Gema Ariceta - Vail Dhebron Hospital, Barcelona, Spain
O-056 Hemodialysis in small children - data from the international pediatric hemodialysis network
Dagmara Borzych-Duzalka - Division for Pediatrics, Nephrology and Hypertension, Medical University of Gdańsk, Poland
13:00 Lunch / Posters: Halls 1&2
13:00-14:00 Industry symposium 6 (Lomond auditorium)
14:00-14:45 Moderated poster session
14:45-15:30 PLENARY SESSION (Lomond auditorium):
Rebuilding a kidney from patient stem cells: what will the future look like?
Melissa Little
15:30-17:00 Parallel sessions
Lomond auditorium JOINT SESSION EWOPA

15:30 History and current state of psychosocial care in paediatric nephrology     
Dirk Bethe, Christopher Reid
16:00 More than just IQ – specific neurocognitive difficulties in children with chronic renal failure and kidney transplantation
Jenny Prüfe
16:15 The sibling voice - The impact of transplantation on siblings
 Gráinne Walsh
16:30 Renal replacement therapy in children with a severe mental disability     
Willem Lore, Elena Levtchenko
Improving the identification and outcomes for paediatric and neonatal acute kidney injury.
15:30 Short and long –term outcomes of neonatal kidney disease
David Askenazi
16:00 How to intervene in pediatric AKI with dialysis
Stefano Picca
16:30 Oral presentations
O-057 European survey on diagnosis and management of crescentic glomerulonephritis in children
Esra Baskin - Baskent University, Ankara, Turkey
O-058 Urinary neutrophil gelatinase-associated lipocalin (NGAL) and serum cystatin C measurements for early diagnosis of acute kidney injury in children
Jameela Kari - Paediatric Nephrology Center of Excellence , Department of Pediatrics, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
O-059 Eculizumab treatment on renal function in paediatric aHUS patients with kidney transplant: data from the aHUS global registry
Choni Rinat - Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel
O-060 Cardiovascular complications in atypical haemolytic uraemic syndrome in children
Khadija Emirova - Moscow State University of Medicine and Dentistry, Russia
Advances in C3 glomerulopathies and dense deposit disease
15:30 Pathogenesis of C3G: from bench to bedside
Christoph Licht
16:00 A clinical approach to C3G
Marina Vivarelli
16:30 Oral presentations
O-061 Detection of convertase-stabilizing factors in patients with complement-mediated renal diseases
Marloes Michels - Radboud University Medical Center, Nijmegen, The Netherlands
O-062 Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents
Jean-Daniel Delbet - Pediatric Nephrology, Armand Trousseau Hospital, APHP, University Pierre and Marie Curie, Paris, France
O-063 Steroid dependent and frequently relapsing nephrotic syndrome is associated with persistent disease into adulthood
Trine Korsgaard - Paediatric and Adolescent Medicine, Aarhus University Hospital, Denmark
O-064 Genetic and clinical characteristics of patients with C3 glomerulopathy
Rezan Topaloglu - Hacettepe University Faculty of Medicine, Department of Pediatric Nephrology, Ankara, Turkey
17:00-18:30 ESPN General Assembly (Lomond auditorium)
19:00-23:30 Gala dinner and ceilidh
Time Saturday 9th
Lomond auditorium Personal practice: What do I do with a child with a cyst in their kidney?
Djalila Mekahli
Boisdale Personal practice: How to recognize and optimally treat AKI in neonates
David Askenazi
8:45-10:15 Parallel sessions
Lomond auditorium
Understanding tubular physiology to improve patient care
08:45 Distal Renal Tubular Acidosis
Fernando Santos
09:15 The molecular basis of non-cystinotic Fanconi syndrome
Francesco Emma
09:45 Oral presentations
O-065 Efficacy and acceptability of ADV7103, an innovative prolonged-release oral alkalising formulation in distal renal tubular acidosis (dRTA) patients
Bertholet-Thomas - Centre de référence des Maladies rénales rares, Néphrogones, Hôpital Femme Mère Enfant, Bron, France- Filière ORKiD
O-066 Chronic kidney disease and renal transplant outcomes in patients with cystinosis
Ewa Elenberg - Texas Children’s Hospital, Baylor College of Medicine, United States
O-067 The role of macrophage activation markers in the therapeutic monitoring of nephropathic cystinosis: a multicentre longitudinal study
Mohamed Ibrahim - KU Leuven, Belgium
O-068 French cohort of transient antenatal Bartter syndrome with MAGED2 mutations
Anne Legrand - Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique and Université Paris Descartes, Faculté de Médecine, Paris, France
Transplanting the untransplantable child
08:45 Blood group and HLA incompatible renal transplantation
Stephen Marks
09:15 Transplanting difficult infants. When and how should we do this?
Hannu Jalanko
09:45 Oral presentations
O-069 Calcineurin inhibitor-induced endothelial cell injury and dysfunction - a role for complement?
Chia Wei Teoh - The Hospital for Sick Children, University of Toronto, Canada
O-070 Urinary proteomics to diagnose chronic-antibody-mediated rejection in pediatric kidney transplantation
Lars Pape - Department of Pediaric Nephrology, Hannover Medical School
O-071 Does the pathogenesis of anaemia differ in renal transplant recipients vs patients with chronic kidney disease?
Cigdem Oruc - Department of Pediatric Nephrology, Istanbul University Cerrahpasa Faculty of Medicine, Turkey
O-072 European Deprivation Index (EDI), a proxy for socio-economic status, is associated with graft outcome in pediatric kidney transplantation: data from the French Renal Registry
Jérôme Harambat - Bordeaux University Hospital, France
Cystic kidney disease/ciliopathies. What have we learnt and where are we going?
08:45 Therapeutic options in treating cystic kidney disease
Max Liebau
09:15 Mechanisms and genetics underpinning paediatric cystic kidney disease
Sophie Saunier
09:45 Oral presentations
O-073 Combined liver-kidney transplantation in children with autosomal recessive polycystic kidney disease (ARPKD) – national center experience
Ryszard Grenda - The Children’s Memorial Health Institute, Warsaw, Poland
O-074 Increased central blood pressure and left ventricular mass index in children with ADPKD
Matko Marlais - Institute of Child Health, London, United Kingdom
O-075 Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease
Stéphanie De Rechter - Department of Pediatric Nephrology, University Hospitals Leuven, Belgium
O-076 Autosomal recessive polycystic kidney disease (ARPKD) in the UK national registry of rare kidney diseases (RaDaR)
Maria Kokocinska - Birmingham Children’s Hospital, United Kingdom
10:15-11:00 PLENARY SESSION (Lomond auditorium):
Digital and global medicine: Organisation and benefits from global networks and multicentre trials.
Franz Schaefer
11:00-11:30 Coffee Break and Exhibition: Halls 1&2
11:30-13:00 Parallel sessions
Lomond auditorium
ESPN registry session
11:30 Ethnic disparities in care and outcome of European children with ESRD: lessons learned from RRT registries
Lidwien Tjaden
11:50 Practice patterns and outcomes of pediatric kidney transplantation in Europe: insights from the ESPN/ERA-EDTA Registry
Jérôme Harambat
12:10 IPNA Registry: challenges and promises of a global RRT registry
Sophie Ploos van Amstel
12:30   Oral presentations
  O-077 Better outcome of Henoch-Schönlein purpura nephritis in children: analysis from the European HSPN registry
Licia Peruzzi - Regina Margherita Hospital, Nephrology Dialysis Transplantation, Turin, Italy
O-078 Recovery of renal function in children on chronic dialysis: A report from the ESPN/ERA-EDTA registry
Marjolein Bonthuis - ESPN/ERA-EDTA Registry, Department of Medical Informatics, University of Amsterdam,  The Netherlands
Personalized and precision medicine in paediatric nephrology
11:30 Pharmacogenomics and personalised medicine
Sir Munir Pirmohamed
12:00 Personalised medicine approach to nephrotic syndrome
Moin Saleem
12:30 Oral presentations
O-079 National vitamin D intoxication outbreak among infants due to a manufacturing error of vitamin D3 droplets
Ida Maria Schmidt - Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Denmark
O-080 Use of herbal and dietary supplements in children with kidney and urinary tract disease
Tugba Tastemel Ozturk - Hacettepe University Faculty of Medicine, Ankara, Turkey
O-081 Improvement of patient, parent/carer experience through high quality information: infoKID
Jan Dudley - Bristol Royal Hospital for Children, United Kingdom
O-082 Pharmacokinetics of enoxaparin in paediatric renal transplantation
Olivia Boyer - Hôpital Necker - Enfants Malades, Institut Imagine, Paris, France
ESPN WG session:The past, present and future of paediatric immune mediated renal disorders
11:30 The past, present and future of paediatric HSP and IgA Nephropathy
Licia Peruzzi
12:00 The past, present and future of paediatric lupus nephritis
Kjell Tullus
12:30 Oral presentations
O-083 Long-term renal outcome in pediatric glomerulonephritis with crescent formation.
Pornpimol Rianthavorn - Department of Pediatrics, Chulalongkorn University, Thailand
O-084 Mycophenolic acid area under the curve is associated with therapeutic response in pediatric lupus nephritis
Jérôme Harambat - Bordeaux University Hospital, France
O-085 Quality of life in idiopathic nephrotic syndrome: comparison between oral immunosuppression and rituximab
Aphaia Roussel - Armand-Trousseau Hospital, Paris and University Upmc, France
O-086 Role of von Willebrand factor (vWF) in endothelial cell repair after complement activation
Christoph Licht - The Hospital for Sick Children, Toronto, Canada
13:00 Closing remarks